Robin F Anders Selected Research

Membrane Proteins (Integral Membrane Proteins)

1/2021	Liposome engraftment and antigen combination potentiate the immune response towards conserved epitopes of the malaria vaccine candidate MSP2.
1/2017	Lipid interactions modulate the structural and antigenic properties of the C-terminal domain of the malaria antigen merozoite surface protein 2.
1/2017	Structure and Characterisation of a Key Epitope in the Conserved C-Terminal Domain of the Malaria Vaccine Candidate MSP2.
5/2015	Structural basis for epitope masking and strain specificity of a conserved epitope in an intrinsically disordered malaria vaccine candidate.
1/2015	Conformational dynamics and antigenicity in the disordered malaria antigen merozoite surface protein 2.
1/2013	Antibodies to polymorphic invasion-inhibitory and non-Inhibitory epitopes of Plasmodium falciparum apical membrane antigen 1 in human malaria.
11/2012	Lipid interactions of the malaria antigen merozoite surface protein 2.
5/2011	Peptide inhibitors of the malaria surface protein, apical membrane antigen 1: identification of key binding residues.
10/2010	Identification of key residues involved in fibril formation by the conserved N-terminal region of Plasmodium falciparum merozoite surface protein 2 (MSP2).
8/2009	Plasmodium falciparum merozoite surface protein 2 is unstructured and forms amyloid-like fibrils.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robin F Anders Research Topics

Disease

42	Malaria 01/2021 - 10/2002
7	Infections 01/2018 - 03/2004
4	Falciparum Malaria (Plasmodium falciparum Malaria) 01/2018 - 04/2005
3	Parasitic Diseases (Parasitic Disease) 01/2017 - 11/2008
3	Parasitemia 02/2016 - 03/2009
2	Communicable Diseases (Infectious Diseases) 01/2016 - 04/2004
2	Reinfection 07/2014 - 11/2012
1	Amyloid Plaque 07/2004
1	Parkinson Disease (Parkinson's Disease) 07/2004
1	Neurodegenerative Diseases (Neurodegenerative Disease) 07/2004
1	Acute malaria 02/2004
1	Asymptomatic Infections 03/2003

Drug/Important Bio-Agent (IBA)

27	AntigensIBA 01/2018 - 03/2003
22	VaccinesIBA 01/2018 - 10/2002
13	Membrane Proteins (Integral Membrane Proteins)IBA 01/2021 - 09/2007
13	AntibodiesIBA 01/2018 - 02/2004
10	Proteins (Proteins, Gene)FDA Link 01/2016 - 07/2004
7	Malaria VaccinesIBA 01/2018 - 06/2003
4	Peptides (Polypeptides)IBA 11/2014 - 10/2002
3	LipidsIBA 01/2017 - 05/2008
3	Immunoglobulin G (IgG)IBA 03/2009 - 01/2009
2	Surface Antigens (Surface Antigen)IBA 01/2021 - 07/2005
2	EpitopesIBA 01/2018 - 01/2013
2	Pharmaceutical PreparationsIBA 08/2014 - 05/2011
2	ImmunosorbentsIBA 03/2009 - 02/2004
1	Complement System Proteins (Complement)IBA 03/2015
1	Intrinsically Disordered ProteinsIBA 01/2015
1	ProteomeIBA 01/2015
1	LigandsIBA 08/2014
1	Biomarkers (Surrogate Marker)IBA 07/2014
1	Antimalarials (Antimalarial Agents)IBA 11/2012
1	Subunit VaccinesIBA 08/2011
1	EmulsionsIBA 01/2011
1	EnzymesIBA 03/2009
1	Fc gamma receptor IIAIBA 03/2009
1	Immunoglobulin IsotypesIBA 01/2009
1	SolutionsIBA 05/2008
1	Monatide (IMS 3015)IBA 04/2005
1	Crystallins (Crystallin)IBA 07/2004
1	Molecular Chaperones (Chaperone, Molecular)IBA 07/2004
1	alpha-SynucleinIBA 07/2004
1	nurse shark antigen receptorIBA 04/2004
1	Serine Proteinase Inhibitors (Serine Protease Inhibitors)IBA 03/2004
1	DNA (Deoxyribonucleic Acid)IBA 03/2003